SAN CARLOS, CA, April 08, 2026 /24-7PressRelease/ -- Marquis Who's Who, the world's premier publisher of biographical profiles, is proud to present Anthony B. Chen, PhD, with the Albert Nelson Marquis Lifetime Achievement Award. An accomplished listee, Dr. Chen celebrates many years' experience in his professional network and has been noted for achievements, leadership qualities, and the credentials and successes he has accrued in his field. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Dr. Chen has established himself as a leading expert in biopharmaceutical product development, with a distinguished career spanning over 40 years. His tenure at Genentech Inc. is marked by a series of progressive roles and groundbreaking achievements that have help shape the biotechnology landscape. Concluding a remarkable chapter at Genentech Inc. in 2025, Dr. Chen served as principal scientist and senior quality assurance specialist from 2009 to 2025. In the latter role he maintained comprehensive oversight of product quality for assigned clinical products across multiple developmental phases and quality functions. He also provided leadership and strategic direction, ensuring reliable clinical supply to patients and representing quality on due diligence projects for product acquisition. Dr. Chen's expertise was instrumental in upholding Genentech's standards of safety and efficacy for clinical trial materials.

Affiliated with Genentech Inc. since 1984, Dr. Chen initially worked in assay development until 1992. He also briefly served as the director of biological chemistry in 1993, overseeing critical method development activities that advanced Genentech's analytical capabilities. He transferred to QC in 1994 to lead a group to introduce rapid and less labor intensive Capillary Electrophoresis (CE) methods to replace time-consuming and laborious gel methods for routine QC use. In three years, Genentech submitted CE methods for release testing of Rituxan in the BLA submitted in 1997. He was also credited with validating analytical, biological and microbiological assays, an accomplishment that set him apart as the only scientist at the organization capable of such comprehensive validation. Dr. Chen's deep understanding of assay methodologies and manufacturing processes made him an invaluable asset to the organization.

Among other accomplishments, Dr. Chen's career was highlighted by his involvement in the development of Rituxan, the first monoclonal antibody submitted for approval by the U.S. Food and Drug Administration and the first from Genentech Inc. He played a key role in its biological characterization and was instrumental in resolving complex challenges during its submission process. Dr. Chen also contributed to the development of Herceptin, another groundbreaking cancer therapy. Beyond these contributions, Dr. Chen collaborated with fellow scientists to develop new products. Additionally, he demonstrated leadership by mentoring colleagues and hiring promising talent.

Headquartered in South San Francisco, Genentech Inc. is recognized as an American biotechnology company that pursues groundbreaking science to discover and develop medicines for individuals with serious and life-threatening diseases. It operates as an independent subsidiary of the holding company Roche.

Dr. Chen's education and work experience prepared him for his innovations at Genentech. Highly educated, Dr. Chen's academic foundation began with a bachelor of science degree in chemistry and biochemistry, earned in 1968, and a master of science degree in immunochemistry in 1970, both from McGill University. He later earned a Doctor of Philosophy in Microbiology from the University of Medicine and Dentistry of New Jersey in Newark, NJ in 1974 and completed post-doctoral studies in Hematology at Downstate Medical Center (1974-1976) and Virology at Vanderbilt University (1976-1978). These academic achievements prepared him for his initial Group Leader position in 1978 at International Diagnostic Technology (IDT), a recent start-up acquired by Boehringer Ingelheim where he developed rapid immunodiagnostic kits for human viral diseases which required FDA approval through the 510K process. Subsequently in 1981, he joined a new start-up company, Daryl Laboratories as Director of Research and Development developing immunoassays for Veterinary Diagnostics with a completely different system he helped develop. Daryl Labs had a veterinary kit approved by the 510K process by the time he left to join Genentech in 1984. These achievements provided Dr. Chen with the scientific rigor and people management skills for his pioneering work at Genentech particularly in developing novel analytical techniques or resolving issues arising during Biological License Applications.

Active in his professional community, Dr. Chen has over 40 publications regarding work that he and his colleagues had performed in the development of methods required for the manufacturing and release testing of recombinant proteins. He has also been recognized throughout his career for his achievements. Dr. Chen played a foundational role in establishing CE Pharm, which has continued over the past 25 years and includes participation from the US Food and Drug Administration. He also received several honors, such as the CE Pharm Award from the CE Pharm Organizing Committee and CASSS in 2008.

Dr. Chen attributes his success to hard work, passion for science and unwavering support from his wife and three daughters. As the first person in his immediate family to attend college, he found inspiration from dedicated mentors throughout his education and postdoctoral studies.

Looking ahead, Dr. Chen remains motivated by Genentech's mission to address unmet medical needs. Having transitioned from a director-level position elsewhere to join Genentech as a scientist focused on discovering cures rather than solely developing detection methods, he is eager to continue making an impact. Dr. Chen hopes to leave behind a legacy defined by innovation, mentorship and an unwavering commitment to improving lives through science. He also hopes to be remembered as someone who consistently sought new solutions through hard work and intellectual curiosity, while never hesitating to seek collaboration when needed.

About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. The suite of Marquis® publications, including Who's Who in America® and Who's Who in the World®, remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the globe. Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.

# # #